Cellife NAD II

Australia - English - Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:
calcium gluconate monohydrate,cyanocobalamin,Cinnamomum cassia,ferrous fumarate,heavy magnesium oxide,leucine,manganese amino acid chelate,menaquinone 7,nicotinamide,nicotinic acid,quercetin,Reynoutria japonica,zinc glycinate
Available from:
Cellife Health Products Pty Ltd
Authorization status:
Authorization number:

Public Summary

Summary for ARTG Entry:


Cellife NAD II

ARTG entry for

Medicine Listed


Cellife Health Products Pty Ltd

Postal Address

PO Box 1090,Burwood North, NSW, 2134


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.


1. Cellife NAD II

Product Type

Single Medicine Product

Effective date


Permitted Indications

Helps reduce/decrease free radical damage to body cells

Helps improve/promote body metabolism/metabolic rate

Maintain/support body tissue repair/regeneration

Indication Requirements

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased

physical activity.

Standard Indications

No Standard Indications included on Record

Specific Indications


Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Keep out of reach of children (or words to that effect).

Not recommended for use by pregnant and lactating women (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Public Summary

Page 1 of

Produced at 29.08.2019 at 04:21:20 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Dosage Form

Tablet, uncoated

Route of Administration


Visual Identification

Active Ingredients

calcium gluconate monohydrate

225 mg

Cinnamomum cassia

50 mg

Equivalent: Cinnamomum cassia (Dry)

500 mg


.0024 mg

ferrous fumarate

25 mg

heavy magnesium oxide

100 mg


100 mg

manganese amino acid chelate

35 mg

menaquinone 7

.06 mg


10 mg

nicotinic acid

100 mg


13 mg

Reynoutria japonica

30 mg

Equivalent: Reynoutria japonica (Dry)

300 mg

zinc glycinate

29 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 29.08.2019 at 04:21:20 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Similar products

Search alerts related to this product

Share this information